Bryce Patrick Portier

Bryce Patrick Portier

Auto-generated profile, based on publicly available information

Bryce Patrick Portier

Medical Affairs, Roche Tissue Diagnostics

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Laboratory Investigation
Verified
Journal Article
Closed access
Rashmi Kanagal-ShamannaRashmi Kanagal-Shamanna
Rashmi Kanagal-Shamanna
BPBryce P Portier
Bryce P Portier
RSRajesh R Singh
Rajesh R Singh
MRMark J Routbort
Mark J Routbort
KAKenneth D Aldape
Kenneth D Aldape
KPKeyur P Patel
Keyur P Patel

1 May 2011 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
GMGruver Aaron M.
Gruver Aaron M.
BPBryce P. Portier
Bryce P. Portier
RTRaymond R. Tubbs
Raymond R. Tubbs
Context .—Adenocarcinoma of the breast is the most frequent cancer affecting women in both developed and developing regions of the world. From the moment of clinical presentation until the time of pathologic diagnosis, patients affected by this disease will face daunting questions related to prognosis and treatment options. While improvements in targeted therapies have led to increased patient survival, these same advances have created the imperative to accurately stratify patients to achieve maximum therapeutic efficacy while minimizing side effects. In this evolving era of personalized medicine, there is an ever-increasing need to overcome the limitations of traditional diagnostic practice. Objective .—To summarize the molecular diagnostics traditionally used to guide prognostication and treatment of breast carcinomas, to highlight published data on the molecular classification of these tumors, and to showcase molecular assays that will supplement traditional methods of categorizing the disease. Data Sources .—A review of the literature covering the molecular diagnostics of breast carcinomas with a focus on the gene expression and array studies used to characterize the molecular signatures of the disease. Special emphasis is placed on summarizing evolving technologies useful in the diagnosis and characterization of breast carcinoma. Conclusions .—Available and emerging molecular resources will allow pathologists to provide superior diagnostic, prognostic, and predictive information about individual breast carcinomas. These advances should translate into earlier identification and tailored therapy and should ultimately improve outcome for patients affected by this disease.

30 August 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BCBenjamin C. Calhoun
Benjamin C. Calhoun
BPBryce Portier
Bryce Portier
ZWZhen Wang
Zhen Wang
EMEugen C. Minca
Eugen C. Minca
GBG. Thomas Budd
G. Thomas Budd
LMLarry E. Morrison
Larry E. Morrison
Pathologic complete response (pCR) after neoadjuvant chemotherapy for breast cancer is associated with improved prognosis in aggressive tumor subtypes, including ERBB2- positive tumors. Recent adoption of pCR as a surrogate endpoint for clinical trials in early stage breast cancer in the neoadjuvant setting highlights the need for biomarkers that, alone or in combination, help predict the likelihood of response to treatment. Biopsy specimens from 29 patients with invasive ductal carcinoma treated with trastuzumab-based therapy prior to definitive resection and pathologic staging were evaluated by dual color bright field in situ hybridization (dual ISH) using probes for MET, TOP2A, PTEN, and PIK3CA genes, each paired with centromeric probes to their respective chromosomes (chromosomes 7, 17, 10, and 3). Ki-67 expression was assessed by immunohistochemistry (IHC). Various parameters describing copy number alterations were evaluated for each gene and centromere probe to identify the optimal parameters for clinical relevance. Combinations of ISH parameters and IHC expression for Ki-67 were also evaluated. Of the four genes and their respective chromosomes evaluated by ISH, two gene copy number parameters provided statistically significant associations with pCR: MET gain or loss relative to chromosome 7 (AUC = 0.791, sensitivity = 92 % and specificity = 67 % at optimal cutoff, p = 0.0032) and gain of PTEN (AUC = 0.674, sensitivity = 38 % and specificity = 100 % at optimal cutoff, p = 0.039). Ki-67 expression was also found to associate significantly with pCR (AUC = 0.726, sensitivity = 100 % and specificity = 42 % at optimal cutoff, p = 0.0098). Combining gain or loss of MET relative to chromosome 7 with Ki-67 expression further improved the association with pCR (AUC = 0.847, sensitivity = 92 % and specificity = 83 % at optimal cutoffs, p = 0.0006). An immunogenotypic signature of low complexity comprising MET relative copy number and Ki-67 expression generated by dual ISH and IHC may help predict pCR in ERBB2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. These findings require validation in additional patient cohorts.

1 July 2006 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
BPBryce Patrick Portier
Bryce Patrick Portier
DFDiana Carolina Ferrari
Diana Carolina Ferrari
GTGiulio Taglialatela
Giulio Taglialatela